Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05025722 · ClinicalTrials.gov registry record
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 48
- Enrollment target
NCT05025722: Completed study, sponsored by Daiichi Sankyo.
NCT05025722 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05025722 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
Study Summary
This PXE biomarker study aims to characterize the levels of inorganic pyrophosphate (PPi), pyridoxal 5´-phosphate (PLP), and other biomarkers relevant to PXE and ectopic calcification in both PXE patients and their biological siblings who are PXE carriers or normal non-PXE individuals.
Primary Outcome
PPi will be assessed by study group and by timepoint where applicable.
Interventions
- OTHER Non Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2022-08-11 |
What the finished NCT05025722 record still lists
NCT05025722 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 48 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Non Interventional is the first listed.
NCT05025722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05025722 about?
NCT05025722 is a clinical study titled "Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings". This PXE biomarker study aims to characterize the levels of inorganic pyrophosphate (PPi), pyridoxal 5´-phosphate (PLP), and other biomarkers relevant to PXE and ectopic calcification in both PXE patients and their biological siblings who are PXE carriers or normal non-PXE individuals.
What is the current status of trial NCT05025722?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2021-08-30. Estimated completion is 2022-08-11.
What interventions are being tested in trial NCT05025722?
The interventions under investigation include: Non Interventional (OTHER).
Who is sponsoring clinical trial NCT05025722?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI